Compare Best Buy Co Inc (BBY) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Best Buy Co Inc vs Twist Bioscience Corp — how do they compare? Best Buy Co Inc trades at $83.6 (market cap $17.55B), while Twist Bioscience Corp trades at $122.96 (market cap $7.72B). The key difference: Best Buy Co Inc is far larger — about 2.3× Twist Bioscience Corp's market cap, and Best Buy Co Inc pays a 4.61% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| BBY | TWST | |
|---|---|---|
Market Cap | $17.55B | $7.72B |
Sector | Consumer Cyclical | Health |
52-Week High | $90.17 | $124.88 |
52-Week Low | $55.52 | $24.16 |
Enterprise Value | $19.93B | $7.65B |
Dividend Yield | 4.61% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Best Buy (BBY) trades at $82.99, up 0.68% on the day, with a neutral technical outlook despite bullish moving averages. The company shows strong profitability with 39.1% ROE and 7.88% ROA, though revenue has declined from $51.8B in 2022 to $41.5B in 2025. Recent leadership changes include a new CFO appointment and marketing chief departure, while the company tests smaller store formats to drive growth.
The stock offers modest upside to the $84.31 consensus target with solid fundamentals but faces revenue pressure and leadership transition risks. Positive cash flow trends and consistent earnings beats support the investment case, though competitive retail pressures and macroeconomic headwinds remain concerns.
Twist Bioscience (TWST) trades at $125.13, up 0.2% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported Q3 2026 revenue of $118.4 million, up 23% year-over-year, beating estimates, but posted a net loss. Revenue growth is strong, yet profitability remains elusive with negative margins. Recent news highlights an upsized $300 million public offering and expanding AI drug discovery pipeline.
Outlook is mixed: robust revenue growth and analyst optimism (78.57% buy ratings) support upside, but persistent losses, cash burn, and high valuation multiples pose significant risks. The stock's proximity to resistance at $126 suggests near-term volatility. Investors should weigh growth potential against financial sustainability concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Best Buy Co Inc
With $51.8 billion in fiscal 2022 sales, Best Buy is the largest pure-play consumer electronics retailer in the U.S., with roughly 10.6% share of the aggregate market and north of 40% share of offline sales, per our calculations, CTA industry, and Euromonitor data. The firm generates the bulk of its sales in-store, with mobile phones and tablets, computers, and appliances representing its three largest categories. Recent investments in e-commerce fulfillment, accelerated by the COVID-19 pandemic, have seen the U.S. e-commerce channel roughly double from prepandemic levels, with management estimating that it will represent a mid-30% proportion of sales moving forward.
Read more on BBY →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
